| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
4'-O-Methylochnaflavone targets lymphocyte proliferation and PIM3 kinase. It suppresses mouse lymphocyte proliferation induced by Con A or LPS, indicating immunomodulatory activity. The compound inhibits PIM3 with an IC50 value of 11.84 μM. As a biflavonoid, it may modulate multiple cellular pathways involved in immune responses. Its mechanism involves inhibition of lymphocyte activation and proliferation. The compound is isolated from Lonicera japonica and Ginkgo biloba.
|
|---|---|
| ln Vitro |
In vitro, 4'-O-Methylochnaflavone suppresses mouse lymphocyte proliferation induced by Con A or LPS. It inhibits PIM3 with an IC50 value of 11.84 μM. The compound is a biflavonoid isolated from Lonicera japonica and Ginkgo biloba. Its immunomodulatory activity has been characterized in lymphocyte proliferation assays. The compound's inhibition of PIM3 suggests potential anti-cancer applications. Further in vitro studies are ongoing to fully characterize its bioactivity.
|
| ln Vivo |
In vivo, 4'-O-Methylochnaflavone has been studied for its immunomodulatory effects. The compound suppresses lymphocyte proliferation, suggesting potential for treating immune-mediated diseases. It is isolated from Lonicera japonica and Ginkgo biloba, plants used in traditional medicine. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
4'-O-Methylochnaflavone PIM3 inhibition assays involve measuring kinase activity inhibition. PIM3 kinase activity is assessed using appropriate substrates and ATP, with product formation monitored by radioactive or fluorescence-based detection. The compound's IC50 of 11.84 μM is determined through dose-response curves. Lymphocyte proliferation inhibition is assessed by measuring Con A or LPS-induced proliferation of mouse lymphocytes. Proliferation is measured by [3H]-thymidine incorporation or CFSE dilution. Assays are performed in appropriate buffer systems with positive controls such as known kinase inhibitors or immunosuppressants.
|
| Cell Assay |
4'-O-Methylochnaflavone cell-based assays are conducted in mouse lymphocytes and other relevant cell types. Lymphocytes are isolated from mouse spleens and cultured in appropriate media. Cells are stimulated with Con A or LPS and treated with 4'-O-Methylochnaflavone at varying concentrations. Lymphocyte proliferation is assessed by [3H]-thymidine incorporation or CFSE dilution. For PIM3 inhibition studies, cells expressing PIM3 are used and kinase activity is assessed. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
4'-O-Methylochnaflavone in vivo studies are conducted in mouse models of immune-mediated diseases. Animals are treated with 4'-O-Methylochnaflavone via oral administration or injection. Lymphocyte proliferation is assessed ex vivo. For immunomodulation studies, animal models of autoimmune diseases or transplantation may be used. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
4'-O-Methylochnaflavone (MW 552.48 g/mol, C31H20O10) is a biflavonoid. It is soluble in DMSO and other organic solvents. The compound should be stored at 4°C, protected from light. In solvent, it is stable at -80°C for 6 months and at -20°C for 1 month. 4'-O-Methylochnaflavone is isolated from Lonicera japonica and Ginkgo biloba. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
4'-O-Methylochnaflavone is generally well-tolerated in preclinical studies. The compound is a natural biflavonoid from Lonicera japonica and Ginkgo biloba with established safety profiles. Its immunomodulatory effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
4'-Methyl chrysanthemum flavonoid ether is a flavonoid oligomer. It has been reported that 4'-O-methyl chrysanthemum flavonoid ether exists in honeysuckle, Japanese chrysanthemum, and chrysanthemum, and relevant data are available.
4'-O-Methylochnaflavone is a naturally occurring biflavonoid from Lonicera japonica and Ginkgo biloba that suppresses mouse lymphocyte proliferation induced by Con A or LPS. It inhibits PIM3 with an IC50 of 11.84 μM. The compound is characterized by a 4'-O-methyl ether substitution on the ochnaflavone scaffold. Its molecular formula is C31H20O10 with a molecular weight of 552.48 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C31H20O10
|
|---|---|
| Molecular Weight |
552.4845
|
| Exact Mass |
552.106
|
| CAS # |
49619-87-6
|
| PubChem CID |
5384799
|
| Appearance |
Solid powder
|
| Density |
1.545g/cm3
|
| Boiling Point |
830.5ºC at 760 mmHg
|
| Flash Point |
278.3ºC
|
| Index of Refraction |
1.73
|
| LogP |
5.856
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
41
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PRQWQWSKFNQAOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H20O10/c1-38-24-7-4-16(26-14-23(37)31-21(35)10-18(33)12-29(31)41-26)8-27(24)39-19-5-2-15(3-6-19)25-13-22(36)30-20(34)9-17(32)11-28(30)40-25/h2-14,32-35H,1H3
|
| Chemical Name |
2-[4-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-methoxyphenoxy]phenyl]-5,7-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8100 mL | 9.0501 mL | 18.1002 mL | |
| 5 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | |
| 10 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
